| GlaxoSmithKline Gets FDA Panel Recommendation For Kidney Cancer Drug Votrient ... - RTT News |
|
|
RTT NewsThe panel indicated the benefit-to-risk profile as acceptable for patients with advanced renal cell carcinoma. Pazopanib is an investigational, ... read more |